Logo image of NLSP

NLS PHARMACEUTICS LTD (NLSP) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:NLSP - CH1384053976 - Common Stock

0.762 USD
+0.02 (+2.97%)
Last: 10/30/2025, 8:00:02 PM
1.08 USD
+0.32 (+41.73%)
After Hours: 10/30/2025, 8:00:02 PM
Fundamental Rating

2

Taking everything into account, NLSP scores 2 out of 10 in our fundamental rating. NLSP was compared to 192 industry peers in the Pharmaceuticals industry. NLSP scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. NLSP is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year NLSP has reported negative net income.
NLSP had a negative operating cash flow in the past year.
In the past 5 years NLSP always reported negative net income.
NLSP had a negative operating cash flow in each of the past 5 years.
NLSP Yearly Net Income VS EBIT VS OCF VS FCFNLSP Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 -5M -10M -15M

1.2 Ratios

The Return On Assets of NLSP (-181.68%) is worse than 87.50% of its industry peers.
NLSP has a worse Return On Equity (-288.47%) than 72.40% of its industry peers.
Industry RankSector Rank
ROA -181.68%
ROE -288.47%
ROIC N/A
ROA(3y)-339.54%
ROA(5y)-292.49%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
NLSP Yearly ROA, ROE, ROICNLSP Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2017 2018 2019 2020 2021 2022 2023 2024 0 -1K -2K -3K

1.3 Margins

NLSP does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
NLSP Yearly Profit, Operating, Gross MarginsNLSP Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2017 2018 2019 2020 2021 2022 2023 2024

More info and screens

6

2. Health

2.1 Basic Checks

NLSP has more shares outstanding than it did 1 year ago.
Compared to 5 years ago, NLSP has less shares outstanding
NLSP has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
NLSP Yearly Shares OutstandingNLSP Yearly Shares OutstandingYearly Shares Outstanding 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M
NLSP Yearly Total Debt VS Total AssetsNLSP Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2017 2018 2019 2020 2021 2022 2023 2024 2M 4M 6M 8M

2.2 Solvency

Based on the Altman-Z score of -47.97, we must say that NLSP is in the distress zone and has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -47.97, NLSP is doing worse than 90.63% of the companies in the same industry.
There is no outstanding debt for NLSP. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -47.97
ROIC/WACCN/A
WACCN/A
NLSP Yearly LT Debt VS Equity VS FCFNLSP Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 0 5M -5M -10M

2.3 Liquidity

NLSP has a Current Ratio of 2.69. This indicates that NLSP is financially healthy and has no problem in meeting its short term obligations.
Looking at the Current ratio, with a value of 2.69, NLSP is in line with its industry, outperforming 51.56% of the companies in the same industry.
NLSP has a Quick Ratio of 2.69. This indicates that NLSP is financially healthy and has no problem in meeting its short term obligations.
NLSP has a Quick ratio (2.69) which is comparable to the rest of the industry.
Industry RankSector Rank
Current Ratio 2.69
Quick Ratio 2.69
NLSP Yearly Current Assets VS Current LiabilitesNLSP Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2017 2018 2019 2020 2021 2022 2023 2024 2M 4M 6M 8M

More info and screens

0

3. Growth

3.1 Past

NLSP shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 77.00%, which is quite impressive.
EPS 1Y (TTM)77%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%79.24%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y97.19%
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
NLSP Yearly EPS VS EstimatesNLSP Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 -50 -100 -150 -200

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for NLSP. In the last year negative earnings were reported.
Also next year NLSP is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
NLSP Price Earnings VS Forward Price EarningsNLSP Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
NLSP Per share dataNLSP EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -1 -2

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

NLSP does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

NLS PHARMACEUTICS LTD

NASDAQ:NLSP (10/30/2025, 8:00:02 PM)

After market: 1.08 +0.32 (+41.73%)

0.762

+0.02 (+2.97%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)05-16 2025-05-16/amc
Earnings (Next)N/A N/A
Inst Owners4.55%
Inst Owner Change0%
Ins Owners20.51%
Ins Owner ChangeN/A
Market Cap4.56M
Revenue(TTM)N/A
Net Income(TTM)-4.06M
Analysts43.33
Price TargetN/A
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 3.25
P/tB 3.25
EV/EBITDA N/A
EPS(TTM)-2.93
EYN/A
EPS(NY)-0.46
Fwd EYN/A
FCF(TTM)-0.71
FCFYN/A
OCF(TTM)-0.71
OCFYN/A
SpS0
BVpS0.23
TBVpS0.23
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -181.68%
ROE -288.47%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-339.54%
ROA(5y)-292.49%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 118.18%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.69
Quick Ratio 2.69
Altman-Z -47.97
F-Score5
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)39.39%
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)77%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%79.24%
EPS Next Y97.19%
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y69.2%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y55.89%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y55.93%
OCF growth 3YN/A
OCF growth 5YN/A

NLS PHARMACEUTICS LTD / NLSP FAQ

What is the fundamental rating for NLSP stock?

ChartMill assigns a fundamental rating of 2 / 10 to NLSP.


What is the valuation status of NLS PHARMACEUTICS LTD (NLSP) stock?

ChartMill assigns a valuation rating of 0 / 10 to NLS PHARMACEUTICS LTD (NLSP). This can be considered as Overvalued.


Can you provide the profitability details for NLS PHARMACEUTICS LTD?

NLS PHARMACEUTICS LTD (NLSP) has a profitability rating of 0 / 10.


What is the financial health of NLS PHARMACEUTICS LTD (NLSP) stock?

The financial health rating of NLS PHARMACEUTICS LTD (NLSP) is 6 / 10.